Core Insights - Microbot Medical Inc. is preparing for the full market release of its LIBERTY Endovascular Robotic System in April 2026, following a successful limited market release that began in late 2025 [3][4] - The company will present at the Roth Annual Growth Conference on March 23, 2026, where CEO Harel Gadot will discuss recent achievements and the unique aspects of the LIBERTY system [1][2] Company Overview - Microbot Medical Inc. is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology [4] - The LIBERTY system is the first FDA cleared, single-use, remotely operated robotic solution designed for precision, efficiency, and safety in peripheral endovascular procedures [3][4] Market Strategy - The company aims to leverage the Roth conference to showcase its commercial momentum and growth story to a diverse audience, which is expected to support its current position and future growth [3] - The LIBERTY system addresses critical unmet healthcare needs, including physician safety and staffing issues, which are increasingly important in the medical field [3]

Core Insights - Microbot Medical Inc. is participating in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference, indicating growing market interest in the company and its products [1][3] - The CEO, Harel Gadot, will present on March 19, 2026, focusing on the achievements and market growth drivers related to the LIBERTY Endovascular Robotic System [1][3] - The LIBERTY system is the first FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, aimed at improving precision and reducing radiation exposure [3][4] Company Overview - Microbot Medical Inc. is a commercial stage medical device company dedicated to transforming endovascular procedures through advanced robotic technology [4] - The LIBERTY Endovascular Robotic System is designed for precision, efficiency, and safety, supported by a strong intellectual property portfolio [4] Market Strategy - The limited market release of the LIBERTY system began in late 2025, with plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026 [3] - The company aims to deepen market adoption by showcasing LIBERTY at key industry events [3]

Core Insights - The LIBERTY Endovascular Robotic System is recognized for its ability to reduce radiation exposure, appealing to hospitals and healthcare providers [1][2] - The American Medical Association (AMA) has adopted a new policy to enhance protections for healthcare professionals against ionizing radiation, highlighting the need for continued research and education [1][3] Company Overview - Microbot Medical Inc. is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology [5] - The LIBERTY System is the first FDA cleared, single-use, remotely operated robotic solution designed for precision, efficiency, and safety in peripheral endovascular procedures [4][5] Technology and Impact - The LIBERTY System allows physicians to perform procedures away from radiation sources, resulting in a 92% relative reduction in radiation exposure as demonstrated in the ACCESS-PVI Study [2][4] - The system's wireless operation reduces reliance on heavy personal protective equipment (PPE), thereby lessening musculoskeletal strain on healthcare providers [3][4] Market Position and Future Plans - The company commenced a Limited Market Release (LMR) of the LIBERTY system in late 2025 and plans a Full Market Release (FMR) at the Society of Interventional Radiology (SIR) conference in April 2026 [4] - The LIBERTY System addresses staffing shortages in the endovascular space, particularly in interventional radiology, which is facing significant physician shortages [3][4]

Core Insights - Microbot Medical Inc. is not experiencing any business disruption due to current geopolitical events, prioritizing employee safety and operational continuity [1][4] - The company has shifted its commercial focus to the U.S. market following FDA clearance of the LIBERTY Endovascular Robotic System, ensuring reliable distribution and service [2] - A full market release of the LIBERTY System is planned for the Society of Interventional Radiology (SIR) conference in April 2026, with efforts to enhance commercial infrastructure [3][5] Company Operations - The company maintains sufficient inventory in the U.S. to support current customers and is actively building additional stock through a third-party logistics partner [2] - Additional sales representatives have been hired to expand coverage into new U.S. territories, along with a Director of Health Economics and Outcomes Research to support commercial expansion [3] Product Information - The LIBERTY System is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, designed to reduce radiation exposure and physical strain [5][6] - The limited market release of the LIBERTY system commenced in late 2025, with the goal of deepening market adoption during the full release [5]

Core Insights - Microbot Medical Inc. has achieved a significant milestone with Tampa General Hospital becoming the first health system in Florida to adopt the LIBERTY Endovascular Robotic System, indicating early post-clearance momentum for advanced robotic solutions in peripheral endovascular procedures [1][2] - The U.S. market for peripheral endovascular procedures is substantial, encompassing approximately 2.5 million procedures annually, presenting a significant clinical and commercial opportunity for the company [1] Company Developments - LIBERTY is the only FDA cleared, single-use, remotely operated robotic system designed for peripheral endovascular procedures, focusing on precise vascular navigation while reducing radiation exposure and physical strain [3][4] - The limited market release of the LIBERTY system commenced in late 2025, with plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026 [3][4] - Microbot Medical is committed to innovation and has a strong intellectual property portfolio, positioning itself to transform endovascular procedures through advanced robotic technology [4] Market Positioning - Tampa General Hospital is recognized for its strong culture of innovation and clinical leadership, making it an ideal partner for the adoption of LIBERTY, which is expected to enhance care delivery and address concerns around radiation safety and ergonomic strain for physicians [2] - The company is actively engaging with additional hospitals during the limited market release and is planning to scale its commercial footprint ahead of the full market release [2]

Core Insights - The LIBERTY Endovascular Robotic System was prominently featured at the International Symposium on Endovascular Therapy (ISET), indicating its growing commercial traction and relevance in the field of endovascular procedures [1][3] Company Overview - Microbot Medical Inc. is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology, with the LIBERTY system being the world's first FDA cleared single-use, remotely operated robotic solution [4] Product Highlights - The LIBERTY Endovascular Robotic System is designed for precision vascular navigation, aiming to reduce radiation exposure and physical strain on clinicians [3] - It is the only FDA cleared, single-use endovascular robotic system, which is expected to drive broader adoption in peripheral endovascular interventions as procedures become more complex [2][3] Market Strategy - The company commenced a limited market release of the LIBERTY system in late 2025 and plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026, aiming to deepen market adoption [3]

Core Insights - Microbot Medical Inc. is participating in the Society of Interventional Oncology (SIO) annual meeting to share insights and experiences regarding its LIBERTY Endovascular Robotic System, which is currently in a limited market release phase [1][2] - The LIBERTY System is the first FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, designed to enhance precision and reduce radiation exposure [3][4] - The company aims to accelerate commercial awareness and adoption of the LIBERTY System through direct engagement with interventional oncologists at the conference [1][2] Company Overview - Microbot Medical Inc. focuses on transforming endovascular procedures with advanced robotic technology, highlighted by the LIBERTY Endovascular Robotic System [4] - The company has a strong intellectual property portfolio and is committed to innovation in the medical device sector [4] Market Context - The interventional oncology market is described as a large and expanding multi-billion dollar sector, with increasing procedure volumes driving demand for advanced technologies like LIBERTY [2] - The full market release of the LIBERTY System is planned for April 2026, coinciding with the Society of Interventional Radiology (SIR) conference [3]

Core Insights - Emory University Hospital has become the first hospital to adopt the LIBERTY Endovascular Robotic System, aligning with its commitment to advancing interventional radiology [1][5] - LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, designed to enhance precision and reduce radiation exposure [2][6] - Microbot Medical is collaborating with Emory to establish an Endovascular Robotics Program, aiming to improve patient care in various peripheral intervention procedures [1][3] Company Overview - Microbot Medical Inc. is focused on transforming endovascular procedures through advanced robotic technology, with LIBERTY being the first FDA-cleared single-use robotic solution [6] - The company emphasizes innovation and has a strong intellectual property portfolio, positioning itself as a leader in the future of endovascular care [6] Market Strategy - The limited market release of LIBERTY has commenced, with plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026 [2] - The adoption of LIBERTY is seen as a significant milestone in the surgical robotic space, reflecting years of dedication and progress by the Microbot team [5]

Core Insights - Stereotaxis (STXS) has launched its Synchrony system in Europe and submitted a 510(k) application to the U.S. FDA, aiming to modernize interventional cath labs with a unified digital interface [1][5] - The Synchrony system enhances workflow, visualization, and connectivity, positioning Stereotaxis to expand its market presence in both robotic and non-robotic cath labs [2][4] Product Features - Synchrony features a 55-inch ultra-high-definition 4K display that integrates multiple system feeds into a single interface, providing near-zero latency video streams and customizable layouts [3] - The system is paired with SynX, a secure cloud-based application that enables remote connectivity, collaboration, and real-time monitoring, compliant with HIPAA and GDPR standards [3][4] Strategic Vision - Synchrony and SynX are foundational platforms designed to support future advancements, including AI-driven automation and long-distance robotic procedures, aligning with Stereotaxis' long-term digital surgery vision [4] - The CE Mark approval allows for commercial rollout in EU markets, while the FDA submission paves the way for potential entry into the U.S. market, enhancing Stereotaxis' geographic reach [5] Competitive Landscape - Stereotaxis competes with key players like Intuitive Surgical (ISRG), which has advanced its da Vinci 5 platform with new software features and gained CE Mark approval for broader international rollout [6][7] - Microbot Medical (MBOT) has achieved FDA clearance for its LIBERTY Endovascular Robotic System, marking a significant milestone in the endovascular robotics market [8][10] - PROCEPT BioRobotics (PRCT) reported strong revenue growth and wider adoption of its Aquablation therapy, indicating a competitive environment in robotic-assisted surgical solutions [11][12]

Core Insights - Microbot Medical Inc. is set to exhibit its LIBERTY Endovascular Robotic System at the upcoming Symposium on Clinical Interventional Oncology, marking its first commercial presence post-FDA clearance [1][2] - The company has completed the recruitment of its commercial leadership team in preparation for the limited market launch of the LIBERTY System, expected in Q4 of this year [2][6] Company Developments - The LIBERTY System will be showcased at booth 208, where interventional oncologists can schedule live hands-on demonstrations [2] - Justin Bourne has joined as Regional Sales Director, bringing 20 years of experience in sales leadership within the healthcare industry, previously at Boston Scientific [3] - Dani Kulp has been appointed as Sales Training Director, with over 15 years of experience in medical education and sales training, focusing on endovascular therapies [4] - Xiomara Ortiz has taken on the role of Marketing Communications Manager, leveraging her extensive experience in digital marketing and brand strategy to enhance the company's brand presence [5] Strategic Outlook - The company has secured a logistics partner and is preparing for the limited market launch of the LIBERTY System, indicating strong momentum since receiving FDA clearance [6] - The addition of key commercial team members is aimed at building a solid foundation for both immediate launch plans and long-term commercial strategy [6] Company Background - Microbot Medical Inc. focuses on transforming endovascular procedures through advanced robotic technology, with the LIBERTY System being the first single-use, remotely operated robotic solution designed for precision and safety [7]